Blood pressure management in the kidney transplant recipient
- PMID: 15216488
- DOI: 10.1053/j.arrt.2004.01.004
Blood pressure management in the kidney transplant recipient
Abstract
Hypertension is extremely common after kidney transplantation. It has been observed in up to 80% to 90% of patients. The etiologies are multifactorial but, in large part, rest with the native kidneys, concomitant immunosuppressant drugs, and behavioral factors that promote the development of higher levels of blood pressure, including obesity, salt intake, smoking, and alcohol consumption. There is a direct relationship between kidney allograft failure and level of systolic blood pressure during follow-up. Patients with a systolic blood pressure greater than 180 mmHg have 2-fold greater risk of loss of graft function compared with patients with systolics of less than 140 mmHg. A similar pattern exists for diastolic blood pressure. Some investigators have also demonstrated that higher levels of blood pressure also correlate with an increased risk of acute graft rejection, particularly in African Americans. What is not known is whether more effective control of arterial pressure in the transplant patient will reduce the likelihood of graft loss and improve survival. No prospective outcome trials have ever been performed. However, it is likely, given the marked success of better control of blood pressure in nontransplant patients in reducing cardiovascular death and the rate of progression of kidney disease, that similar benefits will be appreciated in the transplant patient. Given the greater cardiovascular burden in the kidney transplant recipient because of the presence, in many cases, of diabetes and hypertension, perhaps even more risk reduction may be realized with incremental reductions in blood pressure. Preferred treatment strategies for lowering blood pressure depends on the mechanism of action and medical comorbidity. Drugs that block the renin-angiotensin system should be preferentially considered because they may have similar advantages in delaying progressive loss of allograft function, much in the same way they have proven benefits in protecting native kidney function. Treating blood pressure in the kidney transplant recipient is a complicated process because patients are already on multiple medications and many will need 3 to 5 antihypertensive drugs to achieve optimal control of blood pressure, which should preferably be below 130/80 mmHg.
Similar articles
-
Risk factors for and management of post-transplantation cardiovascular disease.BioDrugs. 2001;15(4):261-78. doi: 10.2165/00063030-200115040-00006. BioDrugs. 2001. PMID: 11437691 Review.
-
Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival.Transplant Proc. 2009 Jul-Aug;41(6):2151-5. doi: 10.1016/j.transproceed.2009.06.134. Transplant Proc. 2009. PMID: 19715859
-
Hypertension in Kidney Transplant Recipients: Where Are We Today?Curr Hypertens Rep. 2021 Apr 13;23(4):21. doi: 10.1007/s11906-021-01139-4. Curr Hypertens Rep. 2021. PMID: 33847830 Review.
-
Hypertension in kidney transplant recipients.Transpl Int. 2011 Jun;24(6):523-33. doi: 10.1111/j.1432-2277.2011.01242.x. Epub 2011 Mar 8. Transpl Int. 2011. PMID: 21382101 Review.
-
[Post-transplant nephropathy and arterial hypertension].Przegl Lek. 2001;58(9):859-63. Przegl Lek. 2001. PMID: 11868248 Review. Polish.
Cited by
-
Management of cardiovascular disease in renal transplant recipients.Clin J Am Soc Nephrol. 2008 Mar;3(2):491-504. doi: 10.2215/CJN.05081107. Epub 2008 Feb 20. Clin J Am Soc Nephrol. 2008. PMID: 18287250 Free PMC article. Review.
-
Hypertension in the Pediatric Kidney Transplant Recipient.Front Pediatr. 2017 May 1;5:86. doi: 10.3389/fped.2017.00086. eCollection 2017. Front Pediatr. 2017. PMID: 28507980 Free PMC article. Review.
-
The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension.Circ Res. 2022 May 13;130(10):1550-1564. doi: 10.1161/CIRCRESAHA.121.320373. Epub 2022 Apr 18. Circ Res. 2022. PMID: 35430873 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical